Literature DB >> 25008143

MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice.

Federica Sala, Juan F Aranda, Noemi Rotllan, Cristina M Ramírez, Binod Aryal, Leonardo Elia, Gianluigi Condorelli, Alberico Luigi Catapano, Carlos Fernández-Hernando1, Giuseppe Danilo Norata2.   

Abstract

The miR-143/145 cluster regulates VSMC specific gene expression, thus controlling differentiation, plasticity and contractile function, and promoting the VSMC phenotypic switch from a contractile/non-proliferative to a migrating/proliferative state. More recently increased miR-145 expression was observed in human carotid atherosclerotic plaques from symptomatic patients. The goal of this study was to investigate the contribution of miR-143/145 during atherogenesis by generating mice lacking miR-143/145 on an Ldlr-deficient background. Ldlr-/- and Ldlr-/--miR-143/145-/- (DKO) were fed a Western diet (WD) for 16 weeks. At the end of the treatment, the lipid profile and the atherosclerotic lesions were assessed in both groups of mice. Absence of miR-143/145 significantly reduced atherosclerotic plaque size and macrophage infiltration. Plasma total cholesterol levels were lower in DKO and FLPC analysis showed decreased cholesterol content in VLDL and LDL fractions. Interestingly miR-143/145 deficiency per se resulted in increased hepatic and vascular ABCA1 expression. We further confirmed the direct regulation of miR-145 on ABCA1 expression by qRT-PCR, Western blotting and 3'UTR-luciferase reporter assays. In summary, miR-143/145 deficiency significantly reduces atherosclerosis in mice. Therapeutic inhibition of miR-145 might be useful for treating atherosclerotic vascular disease.

Entities:  

Keywords:  ABCA1; atherosclerosis; miR-143/145; smooth muscle cells

Mesh:

Substances:

Year:  2014        PMID: 25008143      PMCID: PMC4180777          DOI: 10.1160/TH13-11-0905

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  A unique microRNA signature associated with plaque instability in humans.

Authors:  Francesco Cipollone; Lara Felicioni; Riccardo Sarzani; Sante Ucchino; Francesco Spigonardo; Claudia Mandolini; Sara Malatesta; Marco Bucci; Chiara Mammarella; Donato Santovito; Federica de Lutiis; Antonio Marchetti; Andrea Mezzetti; Fiamma Buttitta
Journal:  Stroke       Date:  2011-08-04       Impact factor: 7.914

Review 2.  Gene silencing approaches for the management of dyslipidaemia.

Authors:  Giuseppe Danilo Norata; Gianpaolo Tibolla; Alberico Luigi Catapano
Journal:  Trends Pharmacol Sci       Date:  2013-02-26       Impact factor: 14.819

3.  Secreted miRNAs suppress atherogenesis.

Authors:  Daniel J Rader; Michael S Parmacek
Journal:  Nat Cell Biol       Date:  2012-02-29       Impact factor: 28.824

4.  Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse.

Authors:  Giuseppe Danilo Norata; Vivek Krishna Pulakazhi Venu; Elisa Callegari; Valentina Paloschi; Alberico Luigi Catapano
Journal:  Biochim Biophys Acta       Date:  2012-02-22

5.  MicroRNA 143-145 deficiency impairs vascular function.

Authors:  G D Norata; C Pinna; F Zappella; L Elia; A Sala; G Condorelli; A L Catapano
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Apr-Jun       Impact factor: 3.219

6.  MicroRNA-145 targeted therapy reduces atherosclerosis.

Authors:  Fina Lovren; Yi Pan; Adrian Quan; Krishna K Singh; Praphulla C Shukla; Nandini Gupta; Brent M Steer; Alistair J Ingram; Milan Gupta; Mohammed Al-Omran; Hwee Teoh; Philip A Marsden; Subodh Verma
Journal:  Circulation       Date:  2012-09-11       Impact factor: 29.690

Review 7.  New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.

Authors:  Giuseppe Danilo Norata; Christie M Ballantyne; Alberico Luigi Catapano
Journal:  Eur Heart J       Date:  2013-03-18       Impact factor: 29.983

Review 8.  MicroRNAs and lipoproteins: a connection beyond atherosclerosis?

Authors:  Giuseppe Danilo Norata; Federica Sala; Alberico Luigi Catapano; Carlos Fernández-Hernando
Journal:  Atherosclerosis       Date:  2012-11-24       Impact factor: 5.162

9.  Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145.

Authors:  Martin H Kang; Lin-Hua Zhang; Nadeeja Wijesekara; Willeke de Haan; Stefanie Butland; Alpana Bhattacharjee; Michael R Hayden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-17       Impact factor: 8.311

10.  Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs.

Authors:  Eduard Hergenreider; Susanne Heydt; Karine Tréguer; Thomas Boettger; Anton J G Horrevoets; Andreas M Zeiher; Margot P Scheffer; Achilleas S Frangakis; Xiaoke Yin; Manuel Mayr; Thomas Braun; Carmen Urbich; Reinier A Boon; Stefanie Dimmeler
Journal:  Nat Cell Biol       Date:  2012-02-12       Impact factor: 28.824

View more
  40 in total

Review 1.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

Authors:  Roopesh S Gangwar; Sanjay Rajagopalan; Rama Natarajan; Jeffrey A Deiuliis
Journal:  Am J Hypertens       Date:  2018-01-12       Impact factor: 2.689

Review 3.  MicroRNA regulation of macrophages in human pathologies.

Authors:  Yuanyuan Wei; Andreas Schober
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

Review 4.  MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis.

Authors:  Andreas Schober; Maliheh Nazari-Jahantigh; Christian Weber
Journal:  Nat Rev Cardiol       Date:  2015-04-07       Impact factor: 32.419

5.  miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1.

Authors:  Yong Wang; Liyan Jin
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

Review 6.  miRNAs and High-Density Lipoprotein metabolism.

Authors:  Ángel Baldán; Thomas Q de Aguiar Vallim
Journal:  Biochim Biophys Acta       Date:  2016-02-09

Review 7.  Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.

Authors:  Suresh Gadde; Katey J Rayner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09       Impact factor: 8.311

8.  MiR-145 improves macrophage-mediated inflammation through targeting Arf6.

Authors:  Rumei Li; Qiwei Shen; Nan Wu; Min He; Naijia Liu; Jinya Huang; Bin Lu; Qiyuan Yao; Yehong Yang; Renming Hu
Journal:  Endocrine       Date:  2018-01-31       Impact factor: 3.633

9.  Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.

Authors:  Jan Novák; Veronika Olejníčková; Nikola Tkáčová; Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

10.  microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

Authors:  Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.